Dumin

Quick links to important sections

Dumin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dumin

Property Description
Active ingredient Paracetamol (Acetaminophen)
Form Caplet, Syrup, Suspension, Rectal preparations
Pharmacological class Non-opioid analgesic, Antipyretic
Common use Relief of mild to moderate pain and fever
Origin Synthetic

1. Dumin: Classification and Core Composition

Dumin is a widely available pharmaceutical preparation primarily classified as a non-opioid analgesic and an antipyretic agent. Its identity is defined by its single, synthetic active ingredient, which is Paracetamol, also globally known by the non-proprietary name Acetaminophen. This core chemical substance places Dumin within the specific pharmacological class recognized for its focused role in pain and fever management, distinguishing it from anti-inflammatory drugs like NSAIDs. Acetaminophen is considered an essential medicine for basic health systems, indicating its status as a foundational therapeutic agent.

2. General Purpose and Benefit

The primary benefit of Dumin is the effective and focused management of both pain and fever, which are its two core therapeutic targets. As an analgesic, Dumin helps relieve mild to moderate pain by affecting how pain signals are processed centrally, while its antipyretic effect works by modulating the body’s central thermoregulation mechanism. Paracetamol is widely used to treat mild pain and reduce fever, making it a reliable staple for symptomatic relief across various common conditions. A typical neutral use scenario involves taking Dumin to relieve a persistent headache or to bring down an elevated temperature.

3. Available Drug Forms and Administration Types

Dumin is positioned to serve a broad target audience through its diverse selection of dosage forms. These pharmaceutical preparations include solid forms like the caplet for oral administration, and liquid forms such as the syrup or suspension for patients who require liquid delivery. For situations where the oral route is unsuitable, preparations such as rectal suppositories are also available, providing an established alternative route of administration.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Acetaminophen (Paracetamol) on NIH/NCBI Bookshelf

What side effects are possible with Dumin?

Possible side effects and safety information

The safety profile of Dumin, which contains the active ingredient Paracetamol (Acetaminophen), is documented by government regulatory agencies through specific classifications of adverse events and safety constraints.

Adverse reactions associated with the medicine at therapeutic doses are generally reported as Rare or Very Rare in official regulatory documents. These are primarily grouped by the following System-Organ Classes (SOCs):

System Organ Class (SOC) Documented Adverse Reactions (Non-Exhaustive)
Hepatobiliary disorders Increased hepatic enzyme levels (transaminases), Hepatic dysfunction
Immune system disorders Hypersensitivity reactions, Anaphylaxis, Angioedema
Blood and lymphatic system Thrombocytopenia, Agranulocytosis, Leucopenia, Neutropenia
Skin and subcutaneous tissue Rash, Urticaria, Pruritus

Serious Adverse Reactions and Safety Constraints

The official labeling highlights specific serious and life-threatening adverse reactions.

  • Severe Hepatotoxicity: Acute liver failure, which may be fatal, is a documented risk, primarily associated with high doses, overdose, or concurrent risk factors.
  • Severe Cutaneous Adverse Reactions (SCARs): Rare but serious skin reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP) are also required warnings in regulatory documents.

Safety is formally constrained by specific patient conditions. The medication is contraindicated in cases of severe active liver disease or known hypersensitivity. Caution is explicitly advised for individuals with severe renal impairment, severe hepatic impairment, chronic alcohol use, or malnutrition, as these conditions may increase the risk of toxicity. Furthermore, official labeling strongly warns against the concomitant use of any other medicine containing Paracetamol (Acetaminophen) to prevent accidental overexposure and subsequent severe liver damage.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Dumin

Overdose Scope Regulatory Documentation Summary
Documented overdose presentations Initial manifestations include non-specific symptoms such as nausea, vomiting, abdominal pain, and diaphoresis (sweating). These early signs may be transient or mimic flu-like illness. Delayed severe manifestations include jaundice (signaling hepatic injury), coma, and seizures.
Physiological systems affected (as stated in label) The primary system affected is the hepatic system (severe hepatic injury, liver failure). Severe toxicological outcomes also involve the renal system (acute renal failure) and the central nervous system.
Dose-related or exposure-related factors (if applicable) Overdose risk is documented for excessive ingestion and specifically noted for repeated supratherapeutic ingestion. Extended-release formulations are specified as requiring prolonged observation.
Population-specific overdose notes (if applicable) Increased risk of severe hepatotoxicity is explicitly stated for patients with underlying severe hepatic impairment, active liver disease, or a history of chronic alcohol use.
Emergency-response statements (as written in official documents) The official action mandated is to seek immediate medical attention or contact a Poison Help center right away.
When immediate medical help is required (label-derived phrasing only) Urgent medical help is required immediately upon the suspicion or knowledge of an overdose, even if the patient is asymptomatic due to the risk of delayed toxicity.

Resulting Overdose Structure

Official overdose statements: • The primary life-threatening outcome documented is severe liver damage leading to acute liver failure, alongside potential renal failure and CNS effects. • The established treatment involves symptomatic and supportive measures, including the specific antidote N-acetylcysteine (NAC), which is time-dependent for efficacy. • Required procedural steps include obtaining a plasma Acetaminophen concentration sample and monitoring hepatic and renal function to determine the course of treatment.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by emphasizing the progression from non-specific early symptoms to severe, potentially fatal organ failure. This structure mandates that emergency help must be sought immediately upon any suspected ingestion beyond the therapeutic range to allow for time-critical monitoring and the timely administration of the documented antidote.

Therapeutic Uses of Dumin

Dumin is applied across domains where additional symptomatic support is needed, most notably for managing pain and fever. It is commonly used for managing mild to moderate pain and for its antipyretic (fever-reducing) effects.

Symptomatic Management of Pain and Discomfort

The medication is commonly used to help with symptoms related to physical discomfort and heightened physiological activity, such as headaches, toothache, and muscular aches. It is relevant for easing symptom clusters that may become intense or disruptive, and may provide supportive relief when symptoms interfere with daily comfort during episodes of common discomfort.

Reducing Elevated Body Temperature (Antipyresis)

Dumin is applied in contexts involving systemic imbalance to address elevated body temperature (fever). It is relevant when short-term symptomatic assistance is needed to help with elevated body temperature associated with conditions like colds and flu or following vaccinations. This use contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Supportive Relief in Acute and Episodic Contexts

The medication is commonly used across conditions presenting with acute episodes or recurrent manifestations, such as managing menstrual cramps or pain associated with minor arthritis. It is often used when symptoms intensify and supportive relief is needed, and may provide support that helps ease the overall symptom burden.

“It is considered relevant in contexts involving heightened systemic burden and may help patients cope more steadily with symptom fluctuations.”


Key Use: Symptomatic support for Pain and Fever


Regulatory References

  1. NIH StatPearls on Acetaminophen Indications

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Dumin

Authoritative governmental regulatory documents, such as those issued by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), define the specific population groups permitted to use a medicine and those who are prohibited (contraindicated) from using it. This information is critical for safe prescribing.

Eligibility Scope Status Based on Official Regulatory Documentation
Populations for whom use is allowed No specific population eligibility statement for a product named Dumin is explicitly available in publicly accessible governmental regulatory documents.
Populations for whom use is contraindicated No formal contraindication statement for Dumin is explicitly available in publicly accessible governmental regulatory documents.

Age, Condition, and Physiological Status

  • Age-Related Eligibility Rules: No specific pediatric, adolescent, or geriatric use rules for Dumin are detailed in publicly available official labeling.
  • Condition-Specific Eligibility Rules: No restrictions related to organ function (e.g., hepatic or renal impairment) are explicitly documented in publicly available official labeling for Dumin.
  • Pregnancy and Lactation Eligibility Status: The eligibility status for individuals who are pregnant or breastfeeding is not explicitly documented in publicly available official labeling for Dumin.

Because no publicly accessible, definitive regulatory labeling for a product named Dumin was found, official information from global health authorities does not currently define strict limits on who can or cannot use this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Statements

The interaction profile of Dumin, which contains the active ingredient Paracetamol (Acetaminophen), is characterized by pharmacokinetic, pharmacodynamic, and administration-timing constraints strictly documented in regulatory labeling. The co-administration of any Other Acetaminophen-Containing Products is a contraindicated combination due to the official risk of accidental overdose leading to severe hepatotoxicity.

Interaction Classification Interacting Substance/Class Regulatory-Documented Outcome
Metabolic (Hepatotoxicity Risk) Hepatic Enzyme Inducers (e.g., Carbamazepine, Phenytoin) Increases the formation of the toxic Paracetamol metabolite, raising the documented risk of liver injury.
Pharmacokinetic (Clearance) Probenecid Reduces the clearance of Dumin, resulting in a documented increase in its plasma concentration.
Pharmacodynamic (Anticoagulant) Warfarin and other Coumarins Prolonged regular daily use enhances the anticoagulant effect, increasing the documented risk of bleeding.

Administration and Substance Constraints

The absorption of Dumin is affected by certain gastrointestinal agents: Metoclopramide and Domperidone are documented to increase the speed of Dumin's absorption, while Cholestyramine significantly reduces it. This reduction requires a mandatory timing separation: Dumin must be administered at least one hour prior to or four to six hours after the administration of Cholestyramine. Chronic, excessive alcohol consumption is an officially documented risk factor for severe liver damage when combined with Dumin. The hazard of overdose-related liver damage is documented as greater in populations with severe hepatic impairment or chronic alcoholism.

Connection to the Overall Interaction Profile

Regulatory documents define Dumin's interaction structure primarily through its metabolic processing and clearance pathways, identifying substances that either accelerate toxic metabolite production or inhibit its elimination, which directly results in a formal contraindication for co-use with other acetaminophen products. The profile is further constrained by absorption kinetics, which require specific timing rules for concurrent administration with agents like Cholestyramine, and includes a key pharmacodynamic constraint tied to the duration of use with oral anticoagulants.

Mechanism of Action

Central Mechanism for Regulating Body Temperature

The mechanism of action for Dumin (Paracetamol/Acetaminophen) is primarily confined to the Central Nervous System (CNS), where it exerts two distinct actions within central physiological pathways. The antipyretic action is focused on the hypothalamus, the brain's thermoregulation center. Dumin works by inhibiting the peroxidase activity of Cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandin E2 (PGE2) locally. Preventing this chemical elevation of the thermal set-point allows the body's internal mechanisms, such as sweating and peripheral vasodilation, to be fully effective, resulting in the adjustment of the thermal set-point and activation of heat-dissipating mechanisms.

Modulation of Central Pain Signaling Pathways

The analgesic action involves the CNS metabolite, AM404, which modulates key receptors in the spinal cord and brainstem. AM404 modulates TRPV1 receptors and indirectly potentiates the cannabinoid CB1 pathway, which are components of the descending nociceptive modulation system. This dual action enhances the activity of these descending pathways that modulate ascending nociceptive input, and alters central processing of nociceptive signals.

Dosage and Administration Information

The use of Dumin must strictly follow the official instructions provided with the medication, which dictate the correct administration procedures and dose schedules.

Administration Scope

Procedural Element Official Labeled Instruction
Route of Administration Oral (tablet/caplet, syrup, drops) and Rectal (suppository).
Standard Dosing Schedule Dosing varies by form and age; for adults, the caplet contains 500 mg of active ingredient, typically taken once daily or as directed.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements Liquid forms (syrup, forte) must be shaken before use to ensure proper mixing. Use the dosing device provided with the package for accurate measurement.
Age-Group Rules Dosing guidelines are specified for different age groups, from infants to the elderly, requiring specific calculation for pediatric use.
Missed-Dose Rules If an oral dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.
Special Conditions Tablets/caplets should be swallowed whole without crushing or chewing. Rectal forms are used when oral consumption is not possible.

Procedural Structure

Official use protocols detail that oral forms are taken by swallowing the tablet/caplet whole, or by accurately measuring the liquid form after shaking. For rectal administration, specific steps for insertion must be followed. Dose adjustments may be required, and patients are directed to strictly adhere to the dose and timing specified on the product label or by a healthcare professional.


Recent Clinical Evidence

Research Evidence / Overview of Studies for Dumin

This overview describes the types of research and studies that have been conducted on Dumin (Paracetamol/Acetaminophen), focusing on the evidence landscape as cited by regulators and scientific bodies. This information is intended to contextualize the available data and does not offer any medical advice or recommendations.


Evidence from Trials for Mild to Moderate Acute Pain

Research involving Dumin for acute physical discomfort is documented in the literature, primarily utilizing Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as headache and short-term muscle aches. Research examined outcomes related to physical discomfort by measuring changes in pain intensity over time, alongside patient reports describing perceived discomfort compared to a placebo.

Studies conducted during periods of increased symptom activity monitored short-term changes in reported pain levels. The outcomes reflecting daily functioning or activity level were often not the main focus. Follow-up durations were typically short (a few hours or days).


Evidence from Trials for Fever (Antipyresis)

Dumin was studied for its role in elevated body temperature in RCTs and systematic reviews. These studies focused on temporary physiological imbalance and involved populations of adults, as well as children and infants. The research examined outcomes related to systemic imbalance by monitoring the change in body temperature and the time it took to observe a reduction.

Research highlights that short-term changes were observed in some studies. Results for temperature reduction were reported to be small when compared to placebo in specific trials. Measures of functional change, beyond the numeric temperature change, are not always fully characterized.


What the Research Literature Still Indicates as Uncertain

The research literature consistently highlights several key areas where findings are either mixed, inconsistent, or limited. Specifically, the magnitude of the measured change may vary considerably depending on the specific cause of the pain, making individual response difficult to predict solely from group data. Comparative evidence is lacking for certain conditions, meaning its relative role against all alternative treatments is not fully understood. Furthermore, long-term effects are not fully established, particularly regarding continuous use for chronic pain conditions.

Key Studies & References

  1. Acetaminophen: Indications, Dosage, Mechanism of Action, and Pharmacokinetics

Frequently Asked Questions (FAQ)

Common questions about Dumin (FAQ)

Q: How quickly does Dumin typically start working after I take it?

Official product information indicates that the therapeutic effect of Dumin, primarily for pain and fever relief, begins relatively quickly. The effect is often reported to be noticeable within 30 to 60 minutes after administration. This timeline is supported by data on how quickly peak concentrations are typically reached.

Q: Does Dumin cause tiredness or affect energy levels?

Official regulatory documents do not commonly list fatigue or tiredness as a frequent adverse reaction when Dumin is used at the recommended therapeutic doses. However, in rare instances or in cases of potential misuse, sleepiness has been mentioned in connection with more serious systemic events.

Q: Does Dumin have a black box warning from the FDA?

Yes, for prescription combination drug products that contain Dumin's active ingredient, the U.S. FDA requires a Boxed Warning. This warning highlights the potential risk for severe liver injury and rare, serious allergic reactions, which are documented to occur particularly with misuse or overdose.

Q: Is it common to feel stomach upset when starting Dumin?

Official regulatory documents list gastrointestinal disturbances such as nausea or stomach pain as potential side effects. However, these are typically noted as rare or very rare occurrences when the medicine is taken as directed, meaning they are not considered a common experience.

Q: Does Dumin change the way birth control pills work?

Some official drug references suggest that the use of high doses of Dumin’s active ingredient may potentially reduce the effectiveness of oral contraceptive pills. This is linked to effects on certain metabolic pathways in the body. Users seeking specific guidance on this interaction should rely on their healthcare professional's advice.

Q: What are the most serious possible side effects listed for Dumin?

The official safety labeling highlights the potential for two very serious types of harm. These are severe liver failure (hepatotoxicity), often linked to overdose, and rare, life-threatening Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Q: Does Dumin affect blood pressure readings?

The active ingredient in Dumin is not consistently listed as a common cause of blood pressure changes. However, some regulatory reviews suggest that chronic, daily use of the medicine may be associated with small increases in systolic blood pressure.

Q: Can women who are planning pregnancy use Dumin?

Studies have not identified a specific risk to fertility or reproductive capacity related to Dumin's active ingredient. Official documents often state that the active ingredient may be considered for use during pregnancy if deemed clinically necessary, generally at the lowest necessary dose for the shortest duration.

Q: How is the benefit of Dumin described in the official research summaries?

Official summaries state that the medicine's effectiveness is supported by randomized controlled trials. The evidence shows effectiveness compared to placebo for the targeted relief of mild to moderate pain and for the reduction of fever (antipyresis).

Q: Are there common signs that Dumin is not working for a person?

Regulatory documentation focuses on measuring therapeutic effect, which is the relief of symptoms. A patient-facing sign that the medicine is not working is simply the persistence of the pain or fever that Dumin was taken to relieve, with no change after the expected time of onset.

Q: What types of drug interactions are generally mentioned in the prescribing information for Dumin?

Interactions documented in official prescribing information are categorized by their effect on the body. These include Metabolic interactions (affecting liver processing), Pharmacokinetic interactions (affecting drug clearance), and Pharmacodynamic interactions (changing the effect of other drugs, like blood thinners).

Q: Is Dumin considered a high-risk medication?

Specific safety organizations list certain formulations, particularly concentrated liquids of the active ingredient, as 'High-Alert Medications.' This designation is used to emphasize the heightened risk of serious harm if a dosing error occurs in an outpatient setting.

Q: What is the purpose of the different strengths Dumin comes in?

Different strengths (e.g., 500 mg, 325 mg) and formulations (liquid, tablet) are made available to allow for accurate and safe dosing across all age groups. This is particularly important for the precise calculation of doses for pediatric patients, which is based on their body weight.

Q: Does Dumin need to be taken at the same time every day?

Regulatory instructions emphasize two key factors: maintaining a minimum interval between doses and ensuring the maximum total dose per 24 hours is not exceeded. The primary focus is maintaining the required interval between doses and not exceeding the safety limits, rather than adhering to a rigid administration time.

Q: Can I drive or operate machinery while taking Dumin?

Official labeling generally indicates that Dumin, at recommended doses, has no or negligible influence on the ability to drive or use machines. Individuals should observe how the medicine affects them, especially concerning any rare side effects that could potentially impair concentration or motor function.

Q: What kind of studies support the use of Dumin?

Official regulatory support for Dumin’s approved uses is based on evidence from Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily compared the drug's effectiveness in reducing pain intensity and lowering body temperature against a placebo.

Q: Is it safe to take Dumin if I already take a daily multivitamin?

Official regulatory documents typically focus interaction warnings on specific prescription drugs, alcohol, and other products that contain the same active ingredient. Standard daily multivitamins are generally not listed as known interacting substances.

Q: Can I take Dumin if I have a history of allergies to other medicines?

Official warnings state that Dumin is contraindicated if a patient has a known hypersensitivity to the active ingredient itself. The official label does not provide definitive guidance on cross-reactivity or allergies related to other, non-chemically related medicines.

Q: Can Dumin be used to treat symptoms in children?

Yes, official regulatory guidelines include specific dosing schedules and concentration recommendations for infants and children. Dosing is typically calculated based on their age and body weight, often using specialized liquid or rectal formulations.

Q: Does Dumin typically need to be adjusted if a patient loses or gains weight?

While the dosage for average-weight adults is generally fixed, specific official clinical guidance notes that individuals who are under a low body weight threshold or have risk factors for liver toxicity are typically subjects for dose review.

Q: Why is Dumin only available by prescription?

The active ingredient is widely available without a prescription in lower strengths. However, specific higher-strength doses or combination products are often legally classified as prescription-only. This classification is primarily a regulatory measure to help manage the risk of accidental overdose and subsequent liver damage.

Q: Can Dumin affect laboratory test results?

Official documents indicate that the medicine may interfere with certain laboratory tests. This interference is most commonly noted for tests used to measure blood sugar (glucose) and, less often, tests for uric acid in urine.

Q: Is Dumin a drug that is used widely around the world?

Yes, the active ingredient in Dumin, Paracetamol/Acetaminophen, is included on the World Health Organization's List of Essential Medicines. This inclusion confirms its importance and status as a foundational therapeutic agent used widely in health systems globally.

Q: Does Dumin require any special monitoring or regular blood tests?

Routine monitoring is generally not required for healthy individuals using the product as directed. Official labeling states that clinical monitoring of hepatic function (liver function) is documented as necessary for patients with pre-existing liver impairment or those on prolonged therapy.

How should Dumin be stored and disposed of?

How to Store and Dispose of Dumin

Official regulatory guidelines for Dumin (Paracetamol) ensure its stability and safe handling.


Storage Requirements

The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. Tablets should be stored at room temperature, typically not exceeding 25 C or 30 C, and must be protected from moisture and excess heat. Always keep Dumin in its original, tightly closed container and do not use any product past the labeled expiry date.


Disposal Instructions

To protect the environment, unused or expired Dumin must not be thrown away via wastewater or household trash. The official procedure is to ask a pharmacist how to properly dispose of the medicine. This ensures disposal through a recognized drug take-back or pharmaceutical waste program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dumin found in:

A-Z Index: